STOCK TITAN

[Form 4] Schrodinger, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Schrodinger, Inc. (SDGR) reported an insider transaction by its Chief Medical Officer, Margaret Dugan. On 10/16/2025, she sold 1,395 shares of common stock at $21.066 per share, coded “S.”

The filing states the sale was executed under a Rule 10b5-1 automatic instruction adopted on November 13, 2023, and was a broker-assisted sale to cover withholding taxes upon the vesting of restricted stock units. Following the sale, she beneficially owns 24,574 shares, which include 20,000 unvested RSUs. Ownership is listed as direct.

Schrodinger, Inc. (SDGR) ha riferito una transazione interna da parte del suo Direttore Medico, Margaret Dugan. Il 16/10/2025 ha venduto 1.395 azioni ordinarie a un prezzo di 21,066 dollari per azione, codificata "S."

La dichiarazione cita che la vendita è stata eseguita ai sensi di un'istruzione automatica Rule 10b5-1 adottata il 13 novembre 2023, ed è stata una vendita assistita da broker per coprire le imposte sul ritenuto al vesting delle RSU (restricted stock units). Dopo la vendita detiene benefici 24.574 azioni, tra cui 20.000 RSU non vestite. La proprietà è elencata come diretta.

Schrodinger, Inc. (SDGR) informó una operación interna por parte de su Directora Médica, Margaret Dugan. El 16/10/2025 vendió 1,395 acciones comunes a 21,066 dólares por acción, codificada "S."

La declaración indica que la venta se realizó bajo una instrucción automática Rule 10b5-1 adoptada el 13 de noviembre de 2023, y fue una venta asistida por un corredor para cubrir impuestos de retención al vestirse de las RSU (restricted stock units). Tras la venta, pasa a poseer 24,574 acciones, que incluyen 20,000 RSU no vestidas. La propiedad se lista como directa.

Schrodinger, Inc. (SDGR) 는 최고의료책임자 Margaret Dugan의 내부거래를 보고했습니다. 2025년 10월 16일 그녀는 보통주 1,395주를 주당 21.066달러에 매각했고, 거래 코드는 “S”입니다.

공시는 이 매도가 2023년 11월 13일에 채택된 Rule 10b5-1 자동지시에 따라 실행되었으며, 제한주식단위(RSU)의 귀속 시점에 대한 원천징수를 충당하기 위한 브로커 보조 매매였다고 명시합니다. 매도 후 그녀는 24,574주를 보유하게 되며, 그중 20,000주는 귀속되지 않은 RSU입니다. 소유권은 직접 보유로 기재됩니다.

Schrodinger, Inc. (SDGR) a annoncé une opération d’intérieur par son Directeur médical, Margaret Dugan. Le 16/10/2025, elle a vendu 1 395 actions ordinaires à 21,066 dollars US par action, codée "S."

Le dossier indique que la vente a été exécutée en vertu d’une instruction automatique Rule 10b5-1 adoptée le 13 novembre 2023, et qu’il s’agissait d’une vente assistée par un courtier pour couvrir les impôts à la source lors du vesting des RSU (restricted stock units). Suite à la vente, elle détient 24 574 actions, dont 20 000 RSU non acquises. La propriété est indiquée comme directe.

Schrodinger, Inc. (SDGR) meldete eine Insider-Transaktion ihrer Chief Medical Officer, Margaret Dugan. Am 16.10.2025 verkaufte sie 1.395 Stammaktien zu 21,066 USD pro Aktie, Kennziffer "S".

Die Einreichung besagt, dass der Verkauf unter einer automatischen Instruction gemäß Rule 10b5-1 erfolgte, die am 13. November 2023 angenommen wurde, und es sich um einen brokereigenen Verkauf handelte, um Steuern auf die vesting-bezogenen RSUs zu decken. Nach dem Verkauf besitzt sie 24.574 Aktien, davon 20.000 unvestete RSUs. Eigentum wird als direkt ausgewiesen.

Schrodinger, Inc. (SDGR) أبلغت عن معاملة داخلية من قبل رئيسها الطبي، مارجريت دوغان. في 16/10/2025، باعت 1,395 سهماً من الأسهم العادية بسعر 21,066 دولاراً للسهم، باستخدام الرمز "S".

تفيد الإيداع بأن البيع تم بموجب تعليمات تلقائية Rule 10b5-1 اعتمدت في 13 نوفمبر 2023، وكان بيعًا بمساعدة وسيط لتغطية ضرائب الاستقطاع عند استحقاق وحدات الأسهم المقيدة RSU. بعد البيع، تملك 24,574 سهماً، من بينها 20,000 RSU غير vesting. الملكية مدرجة كملك مباشر.

Schrodinger, Inc. (SDGR) 报告其首席医疗官 Margaret Dugan 的内部交易。2025年10月16日,她以每股21.066美元的价格出售了1,395股普通股,交易编码为"S"。

披露文件称,该出售是在2023年11月13日通过的 Rule 10b5-1 自动指令下执行的,且是一笔经经纪人协助的出售,用以覆盖限制性股票单位(RSU)归属时的预扣税。出售后,她实际持有24,574股,其中包括20,000股尚未归属的 RSU。所有权被列为直接持有。

Positive
  • None.
Negative
  • None.

Schrodinger, Inc. (SDGR) ha riferito una transazione interna da parte del suo Direttore Medico, Margaret Dugan. Il 16/10/2025 ha venduto 1.395 azioni ordinarie a un prezzo di 21,066 dollari per azione, codificata "S."

La dichiarazione cita che la vendita è stata eseguita ai sensi di un'istruzione automatica Rule 10b5-1 adottata il 13 novembre 2023, ed è stata una vendita assistita da broker per coprire le imposte sul ritenuto al vesting delle RSU (restricted stock units). Dopo la vendita detiene benefici 24.574 azioni, tra cui 20.000 RSU non vestite. La proprietà è elencata come diretta.

Schrodinger, Inc. (SDGR) informó una operación interna por parte de su Directora Médica, Margaret Dugan. El 16/10/2025 vendió 1,395 acciones comunes a 21,066 dólares por acción, codificada "S."

La declaración indica que la venta se realizó bajo una instrucción automática Rule 10b5-1 adoptada el 13 de noviembre de 2023, y fue una venta asistida por un corredor para cubrir impuestos de retención al vestirse de las RSU (restricted stock units). Tras la venta, pasa a poseer 24,574 acciones, que incluyen 20,000 RSU no vestidas. La propiedad se lista como directa.

Schrodinger, Inc. (SDGR) 는 최고의료책임자 Margaret Dugan의 내부거래를 보고했습니다. 2025년 10월 16일 그녀는 보통주 1,395주를 주당 21.066달러에 매각했고, 거래 코드는 “S”입니다.

공시는 이 매도가 2023년 11월 13일에 채택된 Rule 10b5-1 자동지시에 따라 실행되었으며, 제한주식단위(RSU)의 귀속 시점에 대한 원천징수를 충당하기 위한 브로커 보조 매매였다고 명시합니다. 매도 후 그녀는 24,574주를 보유하게 되며, 그중 20,000주는 귀속되지 않은 RSU입니다. 소유권은 직접 보유로 기재됩니다.

Schrodinger, Inc. (SDGR) a annoncé une opération d’intérieur par son Directeur médical, Margaret Dugan. Le 16/10/2025, elle a vendu 1 395 actions ordinaires à 21,066 dollars US par action, codée "S."

Le dossier indique que la vente a été exécutée en vertu d’une instruction automatique Rule 10b5-1 adoptée le 13 novembre 2023, et qu’il s’agissait d’une vente assistée par un courtier pour couvrir les impôts à la source lors du vesting des RSU (restricted stock units). Suite à la vente, elle détient 24 574 actions, dont 20 000 RSU non acquises. La propriété est indiquée comme directe.

Schrodinger, Inc. (SDGR) meldete eine Insider-Transaktion ihrer Chief Medical Officer, Margaret Dugan. Am 16.10.2025 verkaufte sie 1.395 Stammaktien zu 21,066 USD pro Aktie, Kennziffer "S".

Die Einreichung besagt, dass der Verkauf unter einer automatischen Instruction gemäß Rule 10b5-1 erfolgte, die am 13. November 2023 angenommen wurde, und es sich um einen brokereigenen Verkauf handelte, um Steuern auf die vesting-bezogenen RSUs zu decken. Nach dem Verkauf besitzt sie 24.574 Aktien, davon 20.000 unvestete RSUs. Eigentum wird als direkt ausgewiesen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dugan Margaret

(Last) (First) (Middle)
C/O SCHRODINGER, INC.
1540 BROADWAY, 24TH FLOOR

(Street)
NEW YORK NY 10036

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Schrodinger, Inc. [ SDGR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/16/2025 S(1) 1,395 D $21.066 24,574(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This sale was effected pursuant to a durable automatic sale instruction under Rule 10b5-1 adopted by the reporting person on November 13, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). The sale does not represent a discretionary trade by the reporting person.
2. Includes 20,000 unvested RSUs.
Remarks:
/s/ Donald Shum, as attorney-in-fact for Margaret Dugan 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Schrodinger (SDGR) disclose in this Form 4?

The Chief Medical Officer, Margaret Dugan, sold 1,395 shares of common stock on 10/16/2025 at $21.066 per share.

Was the SDGR insider sale discretionary?

No. The filing states it was under a Rule 10b5-1 automatic instruction and broker-assisted to satisfy withholding taxes on RSU vesting.

How many SDGR shares does the insider hold after the transaction?

Beneficial ownership is 24,574 shares following the sale.

How many unvested RSUs does the insider hold at SDGR?

Holdings include 20,000 unvested RSUs.

What is the insider’s role at Schrodinger (SDGR)?

The reporting person is the Chief Medical Officer.

What was the transaction code on the Form 4?

The transaction was coded S (open market or private sale).
Schrodinger, Inc.

NASDAQ:SDGR

SDGR Rankings

SDGR Latest News

SDGR Latest SEC Filings

SDGR Stock Data

1.49B
62.74M
2.62%
108.07%
12.7%
Health Information Services
Pharmaceutical Preparations
Link
United States
NEW YORK